Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes [1]
The international multicenter CE Mark clinical trial of the HeartMate 3 Left Ventricular Assist System included 50 patients. Thirty-day survival was 98%, bleeding and strokes were observed in 30% and 4%, respectively.
Source name:
Eur J Cardiothorac Surg
Resource link:
Subspecialty(ies):
Cardiac [4]